PCI not useful for occluded vessel after completed STEMI
Clinical Question
Does angioplasty and stenting improve outcomes in patients presenting with a completely occluded vessel several days after an ST-elevation myocardial infarction?
Bottom Line
Aggressive angioplasty and stenting of patients with stable angina who present several days after a completed ST-elevation myocardial infarction (STEMI) does not improve important clinical outcomes and may actually increase the long-term risk of reinfarction. (LOE = 1b)
Reference
Hochman JS, Lamas GA, Buller CE, et al, for the Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006;355:2395-2407. [PMID:17105759]
Study Design
Randomized controlled trial (single-blinded)
Funding
Government
Allocation
Concealed
Setting
Inpatient (any location) with outpatient follow-up
Synopsis
Although early intervention with thrombolytics or percutaneous coronary interventions (PCIs) is the current standard of care for patients with STEMI, some patients present late, after the infarct is completed. In this study, high-risk patients presenting with total occlusion of an infarct-related artery between 3 days and 28 days after the STEMI were randomized to receive PCI with stent placement and optimal medical therapy or medical therapy alone. "High risk" was defined as an ejection fraction of less than 50% and/or proximal occlusion of a major coronary artery with a large risk region, and optimal medical therapy included aspirin, an angiotensin-converting enzyme inhibitor, a beta-blocker, lipid lowering therapy, and anticoagulation, if indicated. A total of 2166 patients were included in the study. They had a mean age of 59 years, 78% were men, and 80% were white. The infarct-related artery was the right coronary in 49% of patients and the left anterior descending in 36%. The groups were balanced at the start of the study, analysis was by intention to treat, and outcomes were adjudicated by a monitoring committee blinded to treatment assignment. Patients were followed up for up to 5 years, with a mean follow-up of 2.9 years. At 4 years, there was a trend toward a greater likelihood of nonfatal reinfarction in the PCI group (hazard ratio [HR] = 1.44; 95% CI, 0.96 - 2.16) and for fatal and nonfatal reinfarction (HR = 1.36; 0.92 - 2.00). There was no difference in mortality and no important trends favoring PCI.
Citation
Barry, Henry, et al., editors. "PCI Not Useful for Occluded Vessel After Completed STEMI." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/426103/all/PCI_not_useful_for_occluded_vessel_after_completed_STEMI.
PCI not useful for occluded vessel after completed STEMI. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426103/all/PCI_not_useful_for_occluded_vessel_after_completed_STEMI. Accessed October 12, 2024.
PCI not useful for occluded vessel after completed STEMI. (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426103/all/PCI_not_useful_for_occluded_vessel_after_completed_STEMI
PCI Not Useful for Occluded Vessel After Completed STEMI [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 October 12]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426103/all/PCI_not_useful_for_occluded_vessel_after_completed_STEMI.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - PCI not useful for occluded vessel after completed STEMI
ID - 426103
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426103/all/PCI_not_useful_for_occluded_vessel_after_completed_STEMI
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -